Tesamorelin

About Tesamorelin

Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid protecting group that extends its half-life. It’s the only GHRH analog with FDA approval — for HIV-associated lipodystrophy, specifically because of its selectivity for visceral adipose tissue reduction. What makes tesamorelin notable in metabolic research: it reduces visceral adipose tissue (VAT) by 15–20% in published trials without shifting subcutaneous fat, total body weight, or insulin sensitivity significantly. That VAT-specific effect is rare and makes tesamorelin a valuable tool for isolating visceral-fat pharmacology. IF the research question involves visceral-adipose-tissue pharmacology or GHRH-axis modulation in metabolic syndrome, THEN tesamorelin is the GHRH analog with clinical-grade endpoint data. SO it belongs in NAFLD, metabolic syndrome, and HIV-lipodystrophy research. Lyophilized, ≥99% HPLC.

Specifications

CAS number

106612-94-6

Molecular formula

C221H366N72O67S

Molecular weight

5135.90 g/mol

Purity

>99% HPLC

Form

Lyophilized powder

Storage

Store at 2–8°C